4D Molecular Therapeutics
FDMT
110 hedge funds and large institutions have $534M invested in 4D Molecular Therapeutics in 2023 Q3 according to their latest regulatory filings, with 20 funds opening new positions, 42 increasing their positions, 33 reducing their positions, and 10 closing their positions.
100% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 10
27% more repeat investments, than reductions
Existing positions increased: 42 | Existing positions reduced: 33
10% more funds holding
Funds holding: 100 → 110 (+10)
1.21% more ownership
Funds ownership: 98.47% → 99.68% (+1.2%)
3% more call options, than puts
Call options by funds: $294K | Put options by funds: $286K
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
28% less capital invested
Capital invested by funds: $745M → $534M (-$212M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$18.3M |
| 2 |
Dimensional Fund Advisors
Austin,
Texas
|
+$4.01M |
| 3 |
BlackRock
New York
|
+$3.5M |
| 4 |
NHAS
Novo Holdings A/S
Hellerup,
Denmark
|
+$3.35M |
| 5 |
GC
GMT Capital
Atlanta,
Georgia
|
+$2.53M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$11M |
| 2 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$6.32M |
| 3 |
State Street
Boston,
Massachusetts
|
-$5.57M |
| 4 |
Invesco
Atlanta,
Georgia
|
-$3.31M |
| 5 |
Morgan Stanley
New York
|
-$1.7M |
FDMT Hedge Fund Activity: Q3 2023 in Review
110 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in 4D Molecular Therapeutics (FDMT) for Q3 2023, worth a combined $534M — down 28% from $745M a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new FDMT positions and 10 closed out — a net gain of 10 holders — while 42 added to existing stakes and 33 trimmed.
The largest buyer was RA Capital Management, adding an estimated $18.3M. The largest seller was Deutsche Bank, cutting an estimated $11M.
- 110 institutional investors held 4D Molecular Therapeutics (FDMT) as of Q3 2023, up from 100 in Q2 2023.
- Funds reported $534M of 4D Molecular Therapeutics stock for Q3 2023, down 28% quarter-over-quarter.
- 20 funds opened new 4D Molecular Therapeutics positions in Q3 2023 and 10 closed out, a net change of +10 holders.
- The largest 4D Molecular Therapeutics buyer in Q3 2023 was RA Capital Management, an estimated $18.3M added.
- The largest 4D Molecular Therapeutics seller in Q3 2023 was Deutsche Bank, an estimated $11M sold.
Based on aggregated 13F filings for Q3 2023.